Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Almirall’s collaboration with CrystalO targets novel ion-channel small molecules for medical dermatology, expanding the company’s drug discovery strategy and early-stage dermatology pipeline. Representative image.
Pharma & Biotech

Why Almirall’s latest China biotech deal could open a new small-molecule route into dermatology

Almirall partners with CrystalO on ion-channel small molecules for dermatology. See why clinical proof of concept is the real test for the deal.

Read More
Innate Pharma’s lacutamab partnership with Sobi could unlock the TELLOMAK-3 Phase 3 trial and a potential accelerated approval pathway in T-cell lymphoma, with the licensing agreement carrying up to $580 million in potential value. Representative image.
Pharma & Biotech

What Sobi’s lacutamab licensing deal means for Innate Pharma and TELLOMAK-3

Innate Pharma’s Sobi deal brings $75m upfront and could unlock TELLOMAK-3, accelerated approval and global commercialization of lacutamab.

Read More
MindMaze Therapeutics is sharpening its focus on neurotherapeutics after completing its organizational simplification, while the revised CHF 8 million Neuro.io equity financing schedule puts funding, liquidity and commercial execution in focus. Representative image.
Medical Devices & Diagnostics

MindMaze Therapeutics has finished its portfolio reset, but why is half of the CHF 8m Neuro.io financing still pending?

MindMaze Therapeutics finishes its neurology refocus while CHF 4 million of Neuro.io funding shifts to September and November. See what comes next.

Read More
Akeso advances its breast cancer pipeline as the Phase II AK146D1 study evaluates the TROP2/Nectin-4 bispecific ADC in combination with ivonescimab in advanced HER2-negative breast cancer. Representative image.
Pharma & Biotech

Akeso is betting a dual-target ADC can break through breast cancer’s increasingly crowded treatment field

Akeso starts Phase II testing of AK146D1 plus ivonescimab in advanced breast cancer. See what the dual-target ADC strategy must prove.

Read More
HanchorBio’s collaboration with Taiwan Cancer Moonshot researchers aims to combine multi-omics cancer data with biomarker-driven precision oncology and immunotherapy development, including research relevant to its HCB101 pipeline. Representative image.
Pharma & Biotech

HanchorBio wants biomarkers to sharpen its cancer pipeline. Can Taiwan Cancer Moonshot data deliver?

HanchorBio teams with Taiwan Cancer Moonshot researchers to add multi-omics and biomarker depth to its precision immunotherapy strategy.

Read More
Mabwell’s 9MW0311 and 9MW0321 denosumab biosimilars have passed an ANVISA GMP inspection in Brazil, advancing manufacturing readiness as the company pursues Brazilian marketing authorisation. Representative image.
Pharma & Biotech

Could Brazil become Mabwell’s next denosumab biosimilar market after ANVISA GMP inspection?

Mabwell clears ANVISA GMP inspection for 9MW0311 and 9MW0321, advancing its denosumab biosimilar registration strategy in Brazil.

Read More
Innovent Biologics and Daiichi Sankyo’s VANFLYTA commercialization agreement puts China’s newly diagnosed FLT3-ITD-positive acute myeloid leukemia market in focus as the partners move from regulatory approval toward wider clinical adoption. Representative image.
Pharma & Biotech

What Innovent Biologics’ VANFLYTA deal means for FLT3-ITD AML treatment in China

Innovent Biologics will commercialize Daiichi Sankyo’s VANFLYTA in China after its June approval for newly diagnosed FLT3-ITD AML.

Read More
Silence Therapeutics approaches a key Phase 2 SANRECO trial readout for divesiran in polycythemia vera, with investors and clinicians watching hematocrit control, phlebotomy reduction and the potential of infrequent RNA interference therapy. Representative image.
Pharma & Biotech

What will Silence Therapeutics’ SANRECO Phase 2 results reveal about divesiran in polycythemia vera?

Silence Therapeutics will reveal Phase 2 SANRECO divesiran results in polycythemia vera, testing hematocrit control and phlebotomy reduction.

Read More
Renew Biotechnologies’ NeuroLens research is advancing blood-based cfDNA biomarkers designed to detect neuron-associated signals linked to Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis, highlighting the growing potential of liquid biopsy approaches in neurodegeneration research. Representative image.
Medical Devices & Diagnostics

Can a blood test reveal which neurons are dying? Renew Biotechnologies’ NeuroLens study takes a significant step forward

Renew Biotechnologies has published peer-reviewed proof-of-concept research showing that native cell-free DNA methylation sequencing can recover neuron-associated blood signals that differ across Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. The results strengthen the scientific rationale behind its NeuroLens platform, but the decisive next step is independent, prospective validation in larger and more diverse patient

Read More
Greenstone Biosciences is advancing patient-derived cardiac cell research to identify potential therapies targeting cardiac fibrosis and cardiomyopathy in Duchenne muscular dystrophy following an NIH R61 grant. Representative image.
Pharma & Biotech

Can Greenstone Biosciences turn patient-derived heart cells into a Duchenne cardiomyopathy drug?

Greenstone Biosciences secured an NIH R61 grant to discover cardiac fibrosis drugs for Duchenne muscular dystrophy using iPSC and AI models.

Read More